The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions
Abstract
BACKGROUND: In clinical trials, highly active antiretroviral therapy (HAART) reduces plasma HIV-1 RNA levels to less than 500 copies/mL in 60% to 90% of patients with HIV-1 infection. The performance of such therapy outside of the clinical trial setting is unclear. OBJECTIVE: To determine factors associated with failure to suppress HIV-1 RNA levels and adverse drug reactions in a cohort of patients in whom protease inhibitor-containing therapy was begun in a large urban clinic. DESIGN: Retrospective cohort study. SETTING: Johns Hopkins HIV Clinic in Baltimore, Maryland. PATIENTS: 273 protease inhibitor-naive patients began taking a protease inhibitor regimen containing at least one other antiretroviral drug to which the patients had not previously been exposed. MEASUREMENTS: Demographic variables, plasma HIV-1 RNA levels, CD4+ lymphocyte counts, and adverse drug reactions. RESULTS: Levels of HIV-1 RNA were undetectable in 42% of the cohort at 1 to 90 days, in 44% at 3 to 7 months, and in 37% at 7 to 14 months. Factors associated with failure to suppress viral load at two or more time points included higher rates of missed clinic appointments, nonwhite ethnicity, age 40 years or younger, injection drug use, lower baseline CD4+ lymphocyte count, and higher baseline viral load. In a multivariate model, only higher rates of missed clinic appointments were independently associated with viral suppression at 1 year. Ritonavir was associated with adverse drug reactions about twice as frequently as indinavir or nelfinavir, and women experienced significantly more adverse effects than men. CONCLUSIONS: Unselected patients in whom HAART is started in a clinic setting achieve viral suppression substantially less frequently than do patients in controlled clinical trials. Missed clinic visits were the most important risk factor for failure to suppress HIV-1 RNA levels. Studies are needed to identify interventions that maximize the performance of HAART in inner-city clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Detels, R. (1998) · JAMA · doi:10.1001/jama.280.17.1497 · Cited by 739
Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., & Hamilton, J. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340703 · Cited by 720
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Survival with the Acquired Immunodeficiency Syndrome
Rothenberg, R., Woelfel, M., Stoneburner, R., Milberg, J., Parker, R., & Truman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711193172101 · Cited by 474
Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390504 · Cited by 444
HIV-1 Protease Inhibitors: A Review for Clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.1997.03540260059037 · Cited by 434
Cited by
Impact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., Monforte, A. D., Knysz, B., Dietrich, M., Phillips, A., & Lundgren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13802-0 · Cited by 1,241
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., & Moss, A. (2001) · AIDS · doi:10.1097/00002030-200106150-00015 · Cited by 960
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Stringer, J. S. A., Zulu, I., Levy, J., Stringer, E. M., Mwango, A., Chi, B. H., Mtonga, V., Reid, S., Cantrell, R. A., Bulterys, M., et al. (2006) · JAMA · doi:10.1001/jama.296.7.782 · Cited by 655
Metadata
- Authors
- Lucas, G. M., Chaisson, R. E., & Moore, R. D.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1999-07-20
- Volume
- 131
- Issue
- 2
- Pages
- 81-87
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2078978810
- Cited by
- 843
- References
- 25
- FWCI
- 49.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions. https://app.cochat.ai/papers/10.7326/0003-4819-131-2-199907200-00002
- The paper
- Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999). Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-131-2-199907200-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.